SynthesisBMC pregnancy and childbirth2025
The potential predictive value of miR-181 in women with preeclampsia: a systematic review and meta-analysis.
Synthesis in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultrasound-targeted delivery of miR-513a-5p inhibits ferroptosis and restores vascular function in preeclampsia.Journal of molecular histology · 2026Article
- Investigation of the Impact of miRNA-7151 and a Mutation in Its Target Gene lncRNABiomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPreeclampsia (PE) is a pregnancy-associated disease that result in maternal and fetal morbidity and mortality worldwide. Several studies demonstrated the alterations in miRs (miRNAs) expression in PE. The aim of the present study was to determine the expression level of miR-181 and whether miR-181 have a diagnostic value in detection of women with PE compared to women without PE.
methodsA systematic review and meta-analysis were performed based on studies reporting the miRNA expression level of miR-181 in placenta or serum between pregnant women with and without PE. Thus, articles published up to December 17, 2024 were extracted through PubMed, Scopus, Web of Science and Embase. The electronic literature search was conducted independently by two authors to obtain eligible studies based on the screening of title, abstract and full-text and quality appraisal. Subgroup analyses, area under the curve (AUC) were calculated. Standardized mean difference (SMD) was applied as a measure of pooled effect size.
resultsTwelve studies were included in the systematic review and meta-analysis based on inclusion criteria. The results show that the expression level of miR-181 is significantly higher in women with PE compared to women without PE (SMD = 1.84, 95%CI 0.47-3.21, p = 0.008). No publication bias was observed using the Begg's rank correlation (p = 0.20) and Egger's linear regression (p = 0.57) tests. Subgroup analyses demonstrated significant correlation between miR-181 levels in placenta or serum with maternal age, gestational age at delivery and birth weight. In addition, the pooled AUC was (0.95 ± 0.038; p < 0.0001) that shows the high diagnostic value of miR-181 in women with PE.
conclusionsmiR-181 can be a promising potential biomarker in the early detection of women with PE compared to women without PE. Albeit, further studies are needed for the more confirmation and validation this result.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.